Hypofractionated Radiotherapy for Stage I Non-small Cell Lung Carcinoma in Patients Aged 75 Years and Older


Purpose: We report our single-institution experience using hypofractionated radiotherapy in a patient population 75 years and older diagnosed with stage IA or IB (T1/T2 N0) Non-Small Cell Lung Carcinoma. Materials and methods: This is a single-institution, retrospective analysis examining disease free and overall survival and toxicity after hypofractionated radiation therapy in a patient population 75 years and older diagnosed with stage IA or IB (T1/T2 N0) NSCLC. Between 1991 and 2005, a total of 33 such patients were identified with a median age of 79 years. Patients were treated with a median total dose of 7000 cGy using median daily dose fractions of 250 cGy. Analysis of competing risks (local failure, distal failure or death as the first event) was performed and cumulative incidence functions (CIF) were estimated. Results: The median length of follow-up was 19.8 months (range: 4.3 - 103.8 months). Of the 33 patients treated, 21 (63.6% of total) had no evidence of disease recurrence on follow-up imaging over the course of the study. Of the 12 patients with disease recurrence, 6 (18.2% of total) had local failure as the first event and 6 (18.2% of total) had distant metastasis as the first event. Analysis of competing risks showed that at 5 years, the probability of local failure as the first detected event was 19.5% (95%CI: 7.6%, 35.6%); the probability of distal failure as the first detected event was 21.5% (95%CI: 7.9%,39.4%); and the probability of death without recording a failure was 44.1% (95%CI: 26.1%, 60.7%). There were no treatment related deaths reported. Conclusions: Elderly patients diagnosed with stage I non-small cell lung cancer may safely be offered hypofractionated radiotherapy as an effective option with curative intent.

Share and Cite:

A. Sandhu, K. Messer, M. Fuster, L. Bazhenova, E. Ahmad, M. Pu, P. Nobiensky and S. Seagren, "Hypofractionated Radiotherapy for Stage I Non-small Cell Lung Carcinoma in Patients Aged 75 Years and Older," Journal of Cancer Therapy, Vol. 2 No. 2, 2011, pp. 167-171. doi: 10.4236/jct.2011.22020.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] A. J. Alberg, J. G. Ford and J. M. Samet, “Epidemiology of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition),” Chest, Vol. 132, Supplement 3, 2007, pp. 29S-55S. doi:10.1378/chest.07-1347
[2] W. J. Scott, J. Howington, S. Feigenberg, et al., “Treatment of Non-Small Cell Lung Cancer Stage I and Stage II: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition),” Chest, Vol. 132, Supplement 3, 2007, pp. 234S-242S. doi:10.1378/chest.07-1378
[3] C. Gridelli, P. Maione and A. Rossi, “Treatment of Stage I-III Non-Small-Cell Lung Cancer in the Elderly,” Oncology, Williston Park, Vol. 20, No. 4, 2006, pp. 373-380.
[4] A. Dominguez-Ventura, M. S. Allen, S. D. Cassivi, et al., “Lung Cancer in Octogenarians: Factors Affecting Morbidity and Mortality after Pulmonary Resection,” Annals of Thoracic Surgery, Vol. 82, No. 4, 2006, pp. 1175- 1179. doi:10.1016/j.athoracsur.2006.04.052
[5] A. Sandhu and A. J. Mundt, “Radiation Therapy for Older Cancer Patients,” Aging Health, Vol. 2, No. 6, 2006, pp. 919-930. doi:10.2217/1745509X.2.6.919
[6] D. J. Raz, J. A. Zell, S. H. Ou, et al. “Natural History of Stage I Non-Small Cell Lung Cancer: Implications for Early Detection,” Chest, Vol. 32, No. 1, 2007, pp. 1193-1199.
[7] R. C. McGarry, G. Song, P. des Rosiers, et al., “Observation-Only Management of Early Stage, Medically Inoperable Lung Cancer: Poor Outcome,” Chest, Vol. 121, No. 4, 2002, pp. 1155-1158. doi:10.1378/chest.121.4.1155
[8] P. Bonfili, M. Di Staso, G. L. Gravina, et al., “Hypofractionated Radical Radiotherapy in Elderly Patients with Medically Inoperable Stage I-II Non-Small-Cell Lung Cancer,” Lung Cancer, Vol. 67, No. 1, 2010, pp. 81-85. doi:10.1016/j.lungcan.2009.03.023
[9] M. Pintilie, “Competing Risks: A Practical Perspective,” John Wiley & Sons Ltd., Chichester, 2006.
[10] R. Brookmeyer and J. Crowley “A Confidence Interval for the Median Survival Time,” Biometrics, Vol. 28, 1982, pp. 29-41. doi:10.2307/2530286
[11] A. P. Sandhu, K. Messer, M. M. Fuster, et al., “Definitive Radiation Therapy for Stage I Non-Small-Cell Lung Carcinoma: Institutional Experience with Contemporary Conformal Planning,” Clinical Lung Cancer, Vol. 10, No. 6, 2009, pp. 433-437. doi:10.3816/CLC.2009.n.081
[12] E. Ahmad, A. Sandhu, M. Fuster, et al., “Hypofractionated Radiotherapy as Definitive Treatment of Stage I Non-Small Cell Lung Cancer in Older Patients,” American Journal of Clinical Oncology, Vol. 34, No. 3, 2010, pp. 254-258. doi:10.1097/COC.0b013e3181dea7a3
[13] I. S. Fentiman, U. Tirelli, S. Monfardini, et al., “Cancer in the Elderly: Why So Badly Treated?” Lancet, Vol. 335, 1990, pp. 1020-1022. doi:10.1016/0140-6736(90)91075-L
[14] N. Bayman, N. Alam and C. Faivre-Finn, “Radiotherapy for Lung Cancer in the Elderly,” Lung Cancer, Vol. 68, No. 2, 2010, pp. 129-136. doi:10.1016/j.lungcan.2009.12.004
[15] K. Koga, S. Kusumoto, K. Watanabe, et al., “Age Factor Relevant to the Development of Radiation Pneumonitis in Radiotherapy of Lung Cancer,” International Journal of Radiation Oncology * Biology * Physics, Vol. 14, No. 2, 1988, pp. 367-371. doi:10.1016/0360-3016(88)90445-2
[16] L. Balducci, “Geriatric Oncology: Challenges for the New Century,” European Journal of Cancer, Vol. 36, No. 14, 2000, pp. 1741-1754. doi:10.1016/S0959-8049(00)00169-6

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.